Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.30B P/E - EPS this Y -190.50% Ern Qtrly Grth -
Income -87.18M Forward P/E -19.96 EPS next Y -10.50% 50D Avg Chg 5.00%
Sales 35M PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 6.57 EPS next 5Y - 52W High Chg -30.00%
Recommedations 2.00 Quick Ratio 20.11 Shares Outstanding 49.13M 52W Low Chg 30.00%
Insider Own 12.71% ROA -13.26% Shares Float 26.74M Beta 0.82
Inst Own 91.88% ROE -22.14% Shares Shorted/Prior 3.72M/3.13M Price 67.27
Gross Margin 100.00% Profit Margin -249.10% Avg. Volume 287,355 Target Price 114.80
Oper. Margin -249.00% Earnings Date Nov 10 Volume 795,148 Change 7.43%
SpringWorks Therapeutics, Inc. News
05:30 AM SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma
10/20/21 SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics
10/20/21 SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors
09/07/21 While shareholders of SpringWorks Therapeutics (NASDAQ:SWTX) are in the black over 1 year, those who bought a week ago aren't so fortunate
09/07/21 SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08/30/21 SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
08/13/21 New Strong Sell Stocks for August 13th
08/04/21 SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
08/03/21 SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
08/03/21 SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations
07:00 AM SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer
07/20/21 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
07/19/21 Where Do Hedge Funds Stand On SpringWorks Therapeutics, Inc. (SWTX)?
06/29/21 Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?
06/28/21 Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
06/16/21 SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder
06/16/21 SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
06/15/21 SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference
06/10/21 New Strong Sell Stocks for June 10th

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Chatroom

User Image Last10K Posted - 8 hours ago

$SWTX just filed with the SEC a New Agreement and a Financial Exhibit https://last10k.com/sec-filings/swtx/0001104659-21-130488.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=swtx

User Image cctranscripts Posted - 8 hours ago

Springworks Therapeutics Announces The Initiation Of An Expanded Phase 2 Cohort And Addition Of https://www.conferencecalltranscripts.com/summary/?id=10028039 $SWTX

User Image risenhoover Posted - 8 hours ago

$SWTX / Southwall Technologies files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 SPRINGWORKS THER https://fintel.io/sf/us/swtx?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image Quantisnow Posted - 8 hours ago

$SWTX πŸ“œ SpringWorks Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits https://quantisnow.com/insight/1923005?s=s 30 seconds delayed.

User Image Newsfilter Posted - 8 hours ago

$SWTX Form 8-K: Entry into a Material Definitive Agreement. On October 22, 2021, SpringWorks Therapeutics entered into Amendment No. 1 to that certain Clinical Trial Collaboration and Supply Agreement.. https://newsfilter.io/a/1c0bb257af8e59ed64cc0761dd94eac6

User Image briefingcom Posted - 15 hours ago

$SWTX announces an update from its ongoing clinical collaboration with $GSK evaluating nirogacestat in combination with BLENREP in patients with relapsed or refractory multiple myeloma https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20211027065304SWTX

User Image ChartMill Posted - 17 hours ago

$SWTX: SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Stu ... https://www.chartmill.com/stock/quote/SWTX/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=SWTX&utm_campaign=social_tracking

User Image Stonkmoon Posted - 18 hours ago

$SWTX 2021-10-27 06:30 ET SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma SpringWorks Therapeutics, Inc. https://stonkmoon.com/news/SWTX/2339097bd7d6cde54cf1b64b8c71aea6

User Image cctranscripts Posted - 18 hours ago

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma https://conferencecalltranscripts.com/summary/?id=314515&pr=true $SWTX

User Image STCKPRO Posted - 18 hours ago

$SWTX NEW ARTICLE : SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma https://www.stck.pro/news/SWTX/17131240

User Image fla Posted - 18 hours ago

$SWTX [15s. delayed]: Issued Press Release on October 27, 06:30:00: SpringWorks Therapeutics Announces the Initiation of an Expanded Phase https://s.flashalert.me/Zdiu3

User Image Quantisnow Posted - 18 hours ago

$SWTX πŸ“° SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma https://quantisnow.com/insight/1918570?s=s 30 seconds delayed.

User Image Stock_Titan Posted - 18 hours ago

$SWTX SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma https://www.stocktitan.net/news/SWTX/spring-works-therapeutics-announces-the-initiation-of-an-expanded-mcwo8ktoxx0m.html

User Image Newsfilter Posted - 18 hours ago

$SWTX SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in.. https://newsfilter.io/a/bed3ed679fbb31a4f134c1eb84612e35

User Image SweepCast Posted - 1 day ago

SweepCast alerted: $SWTX with Unusual Options Activity Alerted on $50 PUT Expiring: 12-17-2021 worth 60K🐻 |πŸ₯‡ Start Using SweepCast! https://www.sweepcast.com/optionflow?symbol=SWTX&name=PUT&strike=$50&type=TRADE&pre=$60K&exp=12-17-2021 πŸ₯‡ |

User Image T8skmod Posted - 2 days ago

$SWTX Tweet Stats Today's Change 32% + πŸš€ https://t8sk.com/SWTX

User Image Insider_Analysis Posted - 6 days ago

$SWTX Saqib Islam sold 10,083 shares [High Conviction] www.insider-analysis.com/search_transactions.php?ticker=TABLE_SWTX

User Image Insider_Analysis Posted - 1 week ago

$SWTX Saqib Islam sold 52,417 shares [Very High Conviction] www.insider-analysis.com/search_transactions.php?ticker=TABLE_SWTX

User Image MarketBeatInsiderTrades Posted - 1 week ago

SpringWorks Therapeutics CEO Saqib Islam Sells $591,569.61 in $SWTX https://www.marketbeat.com/i/477773

User Image Newsfilter Posted - 1 week ago

$SWTX $591,569.61 of shares sold by Islam Saqib (Chief Executive Officer), reported in a new form 4 filed with the SEC https://newsfilter.io/a/d9b533d39b696c59aa770da2a1499379

User Image cctranscripts Posted - 1 week ago

SpringWorks Therapeutics, Inc.'s Chief Executive Officer just disposed of 10,083 shares https://www.conferencecalltranscripts.com/summary/?id=10005772 $SWTX

User Image risenhoover Posted - 1 week ago

Insider Saqib Islam reports selling 10,083 shares of $SWTX for a total cost of $591,527.26 https://fintel.io/n/us/swtx/islam-saqib?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image Quantisnow Posted - 1 week ago

$SWTX πŸ“œ SEC Form 4: Islam Saqib sold $591,527 worth of shares (10,083 units at $58.67) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 779,218 units https://quantisnow.com/insight/1897380?s=s This insight appeared 30 seconds early at ⚑ https://quantisnow.com/feed ⚑

User Image InvestorsObserver Posted - 1 week ago

SpringWorks Therapeutics $SWTX Stock Rises After Announcing Computational Oncology Agreement with AbMagnitude https://www.investorsobserver.com/news/stock-update/springworks-therapeutics-swtx-stock-rises-after-announcing-computational-oncology-agreement-with-abmagnitude

User Image briefingcom Posted - 1 week ago

$SWTX to collaborate with ab magnitude on target identification and discovery of next-generation targeted oncology therapeutics https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20211020064622SWTX

User Image briefingcom Posted - 1 week ago

#OnTheWires: $SWTX $TRX $GIB $CYD https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20211020063322WIRES

User Image rxptgh Posted - 1 week ago

$SWTX why so beat up?

User Image ChartMill Posted - 1 week ago

$SWTX: SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Gen ... https://www.chartmill.com/stock/quote/SWTX/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=SWTX&utm_campaign=social_tracking

User Image ChartMill Posted - 1 week ago

$SWTX: SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Ge ... https://www.chartmill.com/stock/quote/SWTX/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=SWTX&utm_campaign=social_tracking

User Image Stonkmoon Posted - 1 week ago

$SWTX 2021-10-20 06:45 ET SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics SpringWorks Therapeutics, Inc. https://stonkmoon.com/news/SWTX/31b87c6fbaf054f0e46be858f0784896

Analyst Ratings
JP Morgan Overweight Sep 8, 21
HC Wainwright & Co. Buy Aug 5, 21
HC Wainwright & Co. Buy Jul 21, 21
HC Wainwright & Co. Buy Feb 25, 21
Barclays Overweight Jan 22, 21
HC Wainwright & Co. Buy Jan 19, 21
HC Wainwright & Co. Buy Dec 28, 20
HC Wainwright & Co. Buy Oct 29, 20
Wedbush Outperform Aug 13, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Islam Saqib Chief Executive Offi.. Chief Executive Officer Oct 18 Sell 58.7 52,417 3,076,878 769,135 10/19/21
Smith L. Mary Chief Development Of.. Chief Development Officer Oct 13 Option 2.3 10,000 23,000 177,511 10/13/21
Smith L. Mary Chief Development Of.. Chief Development Officer Oct 13 Sell 55.97 10,000 559,700 167,511 10/13/21